Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · HALO · as of Sep 30, 2025
Ownership Breakdown
620
Institutional Holders
▲ 53 vs Q2
$8.79B
Total Inst. Value
▲ $2.72B vs Q2
118.61M
Shares Outstanding
freeFloat 98.85%
150.48M
13F Shares Held
▲ 20.35M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
HALO largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
DLD ASSET MANAGEMENT, LP biological products, (no diagnostic substances) | 30.00M | 24.72% | 24.72% | $42.34B | Nov 13, 2025 | ▲ 17.50M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 12.86M | 10.60% | 10.60% | $943.17B | Nov 12, 2025 | ▼ 339.8K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 11.63M | 9.58% | 9.58% | $852.93B | Nov 7, 2025 | ▼ 615.8K |
STATE STREET CORP biological products, (no diagnostic substances) | 5.02M | 4.14% | 4.14% | $368.11B | Nov 14, 2025 | ▼ 915.8K |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 3.29M | 2.71% | 2.71% | $241.34B | Nov 13, 2025 | ▲ 749.5K |
INVESCO LTD. biological products, (no diagnostic substances) | 3.25M | 2.67% | 2.67% | $238.04B | Nov 13, 2025 | ▼ 220.1K |
UBS GROUP AG biological products, (no diagnostic substances) | 2.95M | 2.43% | 2.43% | $216.04B | Nov 13, 2025 | ▲ 1.42M |
SNYDER CAPITAL MANAGEMENT L P biological products, (no diagnostic substances) | 2.73M | 2.25% | 2.25% | $200.50B | Nov 12, 2025 | ▼ 663.9K |
D. E. SHAW & CO., INC. biological products, (no diagnostic substances) | 2.65M | 2.18% | 2.18% | $194.38B | Nov 14, 2025 | ▲ 1.63M |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.43M | 2.00% | 2.00% | $178.34B | Nov 12, 2025 | ▼ 1.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
26
Increased
+27.36M shares1
New Positions
first time holders22
Decreased
−6.61M shares0
Sold Out
fully exitedNet shares change (top 50)
+20.75M
+27.36M / −6.61M
Net new holders
+5
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
HALO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Torley Helen PRESIDENT AND CEO | Jun 1, 2026 | Sale | 1,610 | $66.39 | $106.9K | 786.2K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 400 | $66.37 | $26.5K | 777.4K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 1,500 | $67.67 | $101.5K | 775.9K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 2,000 | $68.74 | $137.5K | 773.9K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 1, 2026 | Sale | 12,989 | $67.41 | $875.6K | 773.2K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 2, 2026 | Sale | 16,600 | $66.31 | $1.10M | 771.2K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 2, 2026 | Sale | 3,400 | $66.75 | $226.9K | 767.8K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 1, 2026 | Sale | 5,401 | $68.35 | $369.1K | 767.8K | Form 4 ↗ |
Torley Helen PRESIDENT AND CEO | Jun 3, 2026 | Sale | 6,100 | $69.69 | $425.1K | 767.8K | Form 4 ↗ |
Connaughton Bernadette director | Jun 1, 2026 | Sale | 1,625 | $66.21 | $107.6K | 43.7K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Halozyme Therapeutics, Inc. (HALO) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 1.15%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Halozyme Therapeutics, Inc. is DLD ASSET MANAGEMENT, LP, holding approximately 30.00 million shares — equal to 24.72% of outstanding shares — as of September 30, 2025.
A total of 620 institutional investors currently hold HALO stock, with a combined institutional value of approximately $8.79 billion as of the most recent 13F filing period.
Frequently asked questions
HALO ownershipHalozyme Therapeutics, Inc. (HALO) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is DLD ASSET MANAGEMENT, LP with a 24.72% stake. Company insiders hold 1.15%. Data sourced from SEC Form 13F as of September 30, 2025.